Fiscal Year: January - December
Waters Corporation (WAT), listed on the NYSE, has a market capitalization of $45.94B. As of Nov 05, 2026, the stock is trading at $467.64 per share@else an unavailable price , offering investors a clear view of its current market value. Waters Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 404.27, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Waters Corporation also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Waters Corporation (WAT) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for Waters Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Waters Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Waters Corporation is 157.98, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Waters Corporation (WAT) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Waters Corporation (WAT) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Waters Corporation (WAT) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Waters Corporation. To access the full SS Score, consider upgrading your subscription.
Waters Corporation is a significant player in the industry sector, with a market capitalization of $45.94B and a competitive P/E ratio of 404.27. Investors should compare these metrics with industry peers to gauge whether Waters Corporation is outperforming or underperforming within its sector.
Piper Sandler raised the firm’s price target on Waters (WAT) to $530 from $480 and keeps an Overweight rating on the shares.
TD Cowen raised the firm’s price target on Waters (WAT) to $530 from $515 and keeps a Buy rating on the shares. The firm updated its model following strong Q3…
RBC Capital raised the firm’s price target on Waters (WAT) to $525 from $475 and keeps an Outperform rating on the shares after its Q3 earnings beat and guidance raise.
KeyBanc raised the firm’s price target on Waters (WAT) to $500 from $460 and keeps an Overweight rating on the shares. The firm notes Waters posted a top- to bottom-line…
JPMorgan analyst Casey Woodring raised the firm’s price target on Waters (WAT) to $470 from $435 and keeps a Neutral rating on the shares.
Citi raised the firm’s price target on Waters (WAT) to $536 from $470 and keeps a Buy rating on the shares.
Stifel analyst Daniel Arias raised the firm’s price target on Waters (WAT) to $470 from $420 and keeps a Hold rating on the shares.
Baird analyst Catherine Ramsey Schulte raised the firm’s price target on Waters (WAT) to $504 from $495 and keeps an Outperform rating on the shares. The firm updated its model…
Barclays raised the firm’s price target on Waters (WAT) to $530 from $500 and keeps an Overweight rating on the shares following the Q3 beat.
Consensus $14.58. Raises FY26 revenue view to $6.48B-$6.5B from $6.42B-$6.48B, consensus $6.46B. Batra continued, “Thanks to the hard work of our teams, we are delivering ahead of schedule on our…
Reports Q3 revenue $1.77B, consensus $1.75B. “Our team delivered exceptional results led by best-in-class consumables growth across both our Analytical Sciences and Biosciences divisions, as strong ex...
Sees Q4 revenue $1.8B-$1.82B, consensus $1.79B. The company said, “The Company expects fourth quarter 2026 organic constant currency revenue growth to be in the range of 7.0% to 9.0%. Including…
Waters (WAT) announced that it has acquired MOBILion Systems. The acquisition broadens Waters’ entry into the proteomics market, pairing SLIM’s separation power with Waters’ Xevo MRT MS speed and reso...
Company to Provide Starting 2027 Growth Framework on Earnings Conference Call Third Quarter 2026 Highlights Total reported revenue of $1.767 billion exceeded guidance midpoint by $14 million, led by o...
Adds MOBILion's breakthrough SLIM high-resolution ion mobility technology, which separates molecules by size, shape and charge in milliseconds, complementing Waters' industry leading mass spectrometry...
Advances Waters' strategy to bring trusted AI, ML, and automation capabilities to the 500,000 Empower™ Software users who run the world's regulated chromatography labs and support the release of over ...
Labcorp (LH) and Waters (WAT) announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network beginning in late 2026. Cervical cance...
Labcorp (LH) and Waters (WAT) announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network beginning in late 2026. Cervical cance...
Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, pati...
Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 First and only FDA-...
Investors looking beyond artificial intelligence (AI) should closely watch two healthcare names – Thermo Fisher Scientific (TMO) and Waters (WAT) – according to Josh Brown. In his latest report, the R...
TD Cowen raised the firm’s price target on Waters (WAT) to $515 from $475 and keeps a Buy rating on the shares. The firm adjusted targets in the life science…
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2026 | 572.19M | 6.00% | Projected |
| 2027 | 606.52M | 6.00% | Projected |
| 2028 | 642.91M | 6.00% | Projected |
| 2029 | 681.48M | 6.00% | Projected |
| 2030 | 722.36M | 6.00% | Projected |
| 2031 | 760.64M | 5.30% | Projected |
| 2032 | 795.63M | 4.60% | Projected |
| 2033 | 826.66M | 3.90% | Projected |
| 2034 | 853.11M | 3.20% | Projected |
| 2035 | 874.44M | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 619.64M | 1.00 | 619.64M |
| 2025A | 539.81M | 1.00 | 539.81M |
| 2026E | 572.19M | 1.09 | Login |
| 2027E | 606.52M | 1.19 | Login |
| 2028E | 642.91M | 1.29 | Login |
| 2029E | 681.48M | 1.41 | Login |
| 2030E | 722.36M | 1.54 | Login |
| 2031E | 760.64M | 1.67 | Login |
| 2032E | 795.63M | 1.82 | Login |
| 2033E | 826.66M | 1.99 | Login |
| 2034E | 853.11M | 2.17 | Login |
| 2035E | 874.44M | 2.36 | Login |
| Terminal | 2.36 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.
